Trial Profile
An Open-Label, Randomized Comparison of Duloxetine, Pregabalin, and the Combination of Duloxetine and Gabapentin Among Patients With Inadequate Response to Gabapentin for the Management of Diabetic Peripheral Neuropathic Pain.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Duloxetine (Primary) ; Gabapentin; Pregabalin
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 18 May 2014 Tolerability results published in the International Journal of Clinical Practice.
- 24 Jun 2010 Results presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA 2010).
- 15 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.